Patterns of Metastasis and Survival in Breast Cancer Patients: A Preliminary Study in an iranian Population

  • Ziaei, Jamal Eivazi (Internal Medicine Department, Hematology Oncology Research Center, Tabriz University of Medical Sciences) ;
  • Pourzand, Ali (General Surgery Department, imamreza Hospital) ;
  • Bayat, Amrollah (General Surgery Department, imamreza Hospital) ;
  • Vaez, Jalil (Internal Medicine Department, Hematology Oncology Research Center, Tabriz University of Medical Sciences)
  • Published : 2012.03.31


Due to lack of sufficient data on characteristics of breast cancer patients and risk factors for developing metastasis in Iran this study was designed to understand clinical aspects impacting on survival. A cross-sectional study on breast cancer patients was conducted in an oncology clinic of the university hospital between 1995 and 2010. Data were retrieved from medical records and included age, menopausal status, tumor diameter, number of involved nodes, histopathological type, estrogen and progesterone receptor expression, c-erbB-2, primary and secondary metastasis sites, overall survival, disease free interval and type of chemotherapy protocol. The results were analyzed with SPSS 13 software. The mean age of the patients was 49.2 (27-89) years. The primary tumors were mainly ER positive (48%) and PR negative (49.3%). The status of lymph nodes dissected and examined in these patients was unknown in 19 patients (25.3%) while 18 patients (24%) had positive lymph nodes with no report on the number of involved nodes. All of the patients had received antracyclin based chemotherapy in an adjuvant or metastatic setting. Adjuvant hormonal therapy was administered to receptor positive patients. In average, overall survival after recurrence was 30 months (95%CI 24.605-35.325) for non-skeletal versus 42 months (95%CI 31.211-52.789) for skeletal metastasis (P= 0.002). The median survival was also greater for receptor positive patients; 39 months (95%CI 33.716-44.284) for PR+ versus 26 months (95%CI 19.210-32.790) for PR- (P=0.047) and 38 months (95%CI 32.908-43.092) for ER+ versus 27 months (95%CI 18.780-35.220) for ER- patients (P=0.016). No relation was found between site of first metastasis and hormone receptor, age, tumor diameter, DFI and menopausal status. Sites of metastasis were independent of age, size of the tumor, menopausal and hormone receptor status in this study. Overall survival provided significant relations with respect to receptor status and bone metastasis.


  1. Balleine RL, Earl MG, Greenbery ML, Clarke CL.(1999). Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer, 79,1564-71.
  2. Chang J, Clark G M, Allred D C, et al (2003). Survival of patients with metastatic breast carcinoma. Cancer, 97, 545-53.
  3. Coleman RE, Smith P, Robens RD (1998). Clinical course and prognostic factors following bone recurrence from breast cancer. Br J cancer, 77, 336-40.
  4. De la Monte S, Hutchins GM, Moore GW (1988). Influence of age on the metastatic behaviour of breast carcinoma. Hum Pathol, 5, 529-34
  5. Harirchi I, Kolahdoozan S, Karbaksh M, et al (2011). Twenty years of breast cancer in Iran: downstaging without a formal screening program. Annals of oncology, 22, 93-7.
  6. Insa A, Lluch A, Prosper F, et al(1999). Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat, 56, 67-78.
  7. Irawan C, Hukom R, Prayogo N (2003). Factors Associated with Bone Metastasis in Breast Cancer: A Preliminary Study in an Indonesian Population, Acta Med Indones- Indones. J Internal Med, 40, 178-80.
  8. James J J, Evans AJ, Pinder S E,et al (2003).Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. Br J Cancer, 18, 660-5.
  9. Kohil HM, Elias EG, Nowiem SA, et al (1985). A multifactorial analysis of steroid hormone receptors in stages I and II breast cancer: Ann Surg.?, ?, 611-7.
  10. Pourzand A, Fakhree M, Hashemzadeh S, Halimi M, Daryani A (2011). Hormone receptor status in breast cancer and its relation to age and other prognostic factors. Breast Cancer (Auckl), 5, 87-92.
  11. Robertson JFR, Jaeger W, Syzmendera JJ,et al (1999). The objective measurement of remission and progression in metastatic breast cancer. Eur J Cancer, 35, 47-53.
  12. Singhakowinta A, Potter H,Buroker T,et al (1976). Estrogen receptor and natural course of breast cancer. Ann Surg, ?, 84-8.
  13. Solomayer E F, Diel IJ, Meyberg GC, Gollan C, Baster G (2000). Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat, 59, 271-8.

Cited by

  1. Targeting Tumor Metastasis by Regulating Nm23 Gene Expression vol.13, pp.8, 2012,
  2. Evolution of sites of recurrence after early breast cancer over the last 20 years: implications for patient care and future research vol.139, pp.2, 2013,
  3. Lymph Node Ratio Assessment of Brain Metastasis in Early Breast Cancer Cases vol.14, pp.3, 2013,